» Articles » PMID: 27188202

Use of a Combined Gene Expression Profile in Implementing a Drug Sensitivity Predictive Model for Breast Cancer

Overview
Specialty Oncology
Date 2016 May 19
PMID 27188202
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Chemotherapy targets all rapidly growing cells, not only cancer cells, and thus is often associated with unpleasant side effects. Therefore, examination of the chemosensitivity based on genotypes is needed in order to reduce the side effects.

Materials And Methods: Various computational approaches have been proposed for predicting chemosensitivity based on gene expression profiles. A linear regression model can be used to predict the response of cancer cells to chemotherapeutic drugs, based on genomic features of the cells, and appropriate sample size for this method depends on the number of predictors. We used principal component analysis and identified a combined gene expression profile to reduce the number of predictors.

Results: The coefficients of determinanation (R) of prediction models with combined gene expression and several independent gene expressions were similar. Corresponding F values, which represent model significances were improved by use of a combined gene expression profile, indicating that the use of a combined gene expression profile is helpful in predicting drug sensitivity. Even better, a prediction model can be used even with small samples because of the reduced number of predictors.

Conclusion: Combined gene expression analysis is expected to contribute to more personalized management of breast cancer cases by enabling more effective targeting of existing therapies. This procedure for identifying a cell-type-specific gene expression profile can be extended to other chemotherapeutic treatments and many other heterogeneous cancer types.

Citing Articles

OBIF: an omics-based interaction framework to reveal molecular drivers of synergy.

Garcia J, Kulkarni V, Reese T, Wali S, Wase S, Zhang J NAR Genom Bioinform. 2022; 4(2):lqac028.

PMID: 35387383 PMC: 8982434. DOI: 10.1093/nargab/lqac028.


Screening and Identification of Differentially Expressed Genes Expressed among Left and Right Colon Adenocarcinoma.

Han J, Zhang X, Yang Y, Feng L, Wang G, Zhang N Biomed Res Int. 2020; 2020:8465068.

PMID: 32420374 PMC: 7201700. DOI: 10.1155/2020/8465068.


Six novel immunoglobulin genes as biomarkers for better prognosis in triple-negative breast cancer by gene co-expression network analysis.

Hsu H, Chu C, Chang Y, Yu J, Chen C, Jian C Sci Rep. 2019; 9(1):4484.

PMID: 30872752 PMC: 6418134. DOI: 10.1038/s41598-019-40826-w.

References
1.
Menden M, Iorio F, Garnett M, McDermott U, Benes C, Ballester P . Machine learning prediction of cancer cell sensitivity to drugs based on genomic and chemical properties. PLoS One. 2013; 8(4):e61318. PMC: 3640019. DOI: 10.1371/journal.pone.0061318. View

2.
Ring B, Chang S, Ring L, Seitz R, Ross D . Gene expression patterns within cell lines are predictive of chemosensitivity. BMC Genomics. 2008; 9:74. PMC: 2263043. DOI: 10.1186/1471-2164-9-74. View

3.
Jung K, Won Y, Oh C, Kong H, Cho H, Lee J . Prediction of Cancer Incidence and Mortality in Korea, 2016. Cancer Res Treat. 2016; 48(2):451-7. PMC: 4843733. DOI: 10.4143/crt.2016.092. View

4.
Kao J, Salari K, Bocanegra M, Choi Y, Girard L, Gandhi J . Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PLoS One. 2009; 4(7):e6146. PMC: 2702084. DOI: 10.1371/journal.pone.0006146. View

5.
Lee J, Havaleshko D, Cho H, Weinstein J, Kaldjian E, Karpovich J . A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery. Proc Natl Acad Sci U S A. 2007; 104(32):13086-91. PMC: 1941805. DOI: 10.1073/pnas.0610292104. View